Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sachs

Showing results (181-190 of 185) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 185 results.
Ebiomedicine|January 18, 2022
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trialFrédéric Vanhoutte, Wen Liu, Richard T Wiedmann, et al.
Journal of Proteome Research|January 26, 2010
Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometryCloud P Paweletz, Matthew C Wiener, Andrey Y Bondarenko, et al.
Ebiomedicine|July 9, 2022
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trialJonathan A Robbins, Dereck Tait, Qinlei Huang, et al.
Ebiomedicine|November 14, 2021
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxisBrian M Maas, Jos Lommerse, Nele Plock, et al.
Plos One|August 14, 2015
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal FluidRonald C Hendrickson, Anita Y H Lee, Qinghua Song, et al.
Pageof 19

Showing results (181-190 of 185) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 185 results.
Ebiomedicine|January 18, 2022
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trialFrédéric Vanhoutte, Wen Liu, Richard T Wiedmann, et al.
Journal of Proteome Research|January 26, 2010
Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometryCloud P Paweletz, Matthew C Wiener, Andrey Y Bondarenko, et al.
Ebiomedicine|July 9, 2022
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trialJonathan A Robbins, Dereck Tait, Qinlei Huang, et al.
Ebiomedicine|November 14, 2021
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxisBrian M Maas, Jos Lommerse, Nele Plock, et al.
Plos One|August 14, 2015
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal FluidRonald C Hendrickson, Anita Y H Lee, Qinghua Song, et al.
Pageof 19